Arvinas

The global targeted protein degradation market is projected to grow from USD 0.548 billion in 2023 to USD 4.37 billion by 2034, driven by precision medicine, drug discovery investments, and technological advancements. PROTACs lead the market, with molecular glues expected to grow fastest. Therapy development dominates applications, particularly in cancer and neurodegenerative diseases. Pharmaceutical & biotechnology companies are the largest end-users. North America leads in revenue, while Asia-Pacific shows the highest growth rate.

Arvinas and Pfizer announced preliminary Phase 1b data showing 62.5% clinical benefit rate for vepdegestrant plus abemaciclib in advanced breast cancer patients previously treated with CDK4/6 inhibitors. The combination demonstrated a tolerable safety profile and no significant drug-drug interaction. Data will be presented at the 2024 San Antonio Breast Cancer Symposium.

Neutropenia treatment market to reach USD 20.8 billion by 2032, driven by cancer prevalence and chemotherapy-induced neutropenia. Rising R&D leads to new therapies like G-CSFs and oral treatments. Idiopathic neutropenia and APAC market growth are significant. Key players include Amgen, Pfizer, and Teva.